# Program 1 Architecture Review Track Phase C - Conceptual Data Flow and Synthetic Boundary Trace

Status: documentation-only, synthetic-only, non-production, non-runtime, pre-implementation, conceptual data-flow review. Not an implementation authorization and not a runtime data-flow authorization.

## Purpose

Program 1 Architecture Review Track Phase C defines conceptual data-flow boundaries using only synthetic entities, abstract placeholders, and documentation-only traces.

Phase C follows Architecture Review Track Phase A and Phase B. It is not Phase Z+1 and is not a return to the Phase V-Z governance/prototype sequence.

Program 1 remains in pre-implementation hold.

## Track continuity

Phase A established the synthetic-only architecture boundary. Phase B established conceptual module separation and prohibited coupling paths. Phase C traces conceptual synthetic-only data movement between those conceptual layers without creating runtime data flow, real-data ingestion, PHI/PII processing, write-back behavior, patient messaging, appointment mutation, workflow enforcement, audit capture, RBAC enforcement, or approval/override capability.

## Scope

- Synthetic entity model.
- Documentation-only conceptual data-flow model.
- Allowed synthetic trace paths.
- Prohibited real-data flow paths.
- Read-only conceptual flow boundary.
- Write-back and mutation prohibition trace.
- Security, audit, and authorization conceptual flow limits.
- Boundary trace matrix.

## Non-scope

Phase C does not add runtime code, tests, helpers, scripts, imports, services, database migrations, API endpoints, UI flows, schedulers, task runners, integrations, data connectors, real-data ingestion, PHI/PII processing, runtime auth/authz/RBAC, runtime audit logging, patient messaging, appointment mutation, workflow enforcement, Task engine, Outcome Evidence, clinical write workflows, approval/clearance/override runtime capability, production-readiness claim, or go-live authorization.

## Safety boundaries

Phase C is documentation-only, synthetic-only, non-production, non-runtime, pre-implementation, conceptual only, not an implementation authorization, not a production-readiness review, not a clinical deployment review, and not a runtime data-flow authorization.

Phase C does not approve production use, real patient data, PHI/PII processing, live clinical deployment, clinical validation, operational clearance, go-live, runtime implementation, runtime data flow, real-data ingestion, database integration, or approval/clearance/override behavior.

## Phase A/B input summary

Phase A established synthetic-only architecture boundaries, permitted future discussion areas, prohibited runtime paths, data classification preview, read-only vs write-capable conceptual distinction, human-in-the-loop responsibility preview, and a future approval dependency map.

Phase B established conceptual module separation, the synthetic documentation layer boundary, future read-only layer boundary, future clinical review layer boundary, prohibited write-capable layer boundary, prohibited patient communication boundary, prohibited appointment mutation boundary, deferred security/audit/authorization layer, and prohibited coupling map.

## Synthetic entity model

| Synthetic entity | Purpose | Allowed current use | Prohibited current use | May represent real patient data? | May contain PHI/PII? | May trigger runtime action? | Current decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| SyntheticPatient | Abstract person placeholder | Text-only architecture discussion | Real patient profile or identifier | No | No | No | Synthetic-only |
| SyntheticEncounter | Abstract interaction placeholder | Conceptual encounter trace | Real appointment or visit record | No | No | No | Synthetic-only |
| SyntheticFinding | Abstract finding placeholder | Conceptual finding trace | Real clinical finding | No | No | No | Synthetic-only |
| SyntheticRecommendationPlaceholder | Abstract recommendation placeholder | Conceptual review output discussion | Patient instruction or treatment execution | No | No | No | Synthetic-only |
| SyntheticClinicianReviewPlaceholder | Abstract human review placeholder | Conceptual human-in-the-loop trace | Clinical validation or deployment | No | No | No | Synthetic-only |
| SyntheticAppointmentPlaceholder | Abstract scheduling placeholder | Prohibition discussion only | Appointment creation, cancellation, reschedule, or status change | No | No | No | Synthetic-only |
| SyntheticMessagePlaceholder | Abstract communication placeholder | Prohibition discussion only | Patient message, reminder, portal output, or staff-mediated patient instruction | No | No | No | Synthetic-only |
| SyntheticAuditConcept | Abstract audit concept | Deferred audit discussion only | Runtime audit capture or storage | No | No | No | Synthetic-only |
| SyntheticAuthorizationConcept | Abstract authorization concept | Deferred authorization discussion only | Runtime access grant, RBAC, or policy enforcement | No | No | No | Synthetic-only |
| SyntheticOutcomePlaceholder | Abstract outcome placeholder | Prohibition discussion only | Outcome Evidence creation | No | No | No | Synthetic-only |

Every synthetic entity is synthetic-only and must not represent, derive from, or be mapped to real patient data.

## Conceptual data-flow model

Conceptual flows may be described between the synthetic documentation layer, architecture review layer, future read-only reference concept, future clinical review concept, deferred security/audit/authorization concepts, and prohibited write-capable concepts.

All flows are text-only, non-runtime, synthetic-only, non-executable, non-integrated, non-deployable, and not connected to real systems.

## Allowed synthetic trace paths

| Source | Target | Allowed current interpretation | Prohibited interpretation | Runtime status | Data boundary | Current decision |
| --- | --- | --- | --- | --- | --- | --- |
| SyntheticPatient | SyntheticEncounter | Synthetic conceptual relationship | Real patient visit flow | None | Synthetic only | Allowed as documentation trace only |
| SyntheticEncounter | SyntheticFinding | Synthetic conceptual finding relationship | Real clinical finding extraction | None | Synthetic only | Allowed as documentation trace only |
| SyntheticFinding | SyntheticClinicianReviewPlaceholder | Synthetic review concept | Clinical deployment or validation | None | Synthetic only | Allowed as documentation trace only |
| SyntheticClinicianReviewPlaceholder | SyntheticRecommendationPlaceholder | Human review concept | Treatment execution or patient instruction | None | Synthetic only | Allowed as documentation trace only |
| SyntheticAppointmentPlaceholder | Architecture review discussion only | Prohibited scheduling discussion | Appointment mutation | None | Synthetic only | Allowed as prohibition trace only |
| SyntheticMessagePlaceholder | Prohibited communication discussion only | Prohibited communication discussion | Patient messaging | None | Synthetic only | Allowed as prohibition trace only |
| SyntheticAuditConcept | Deferred audit discussion only | Audit architecture concept | Runtime audit capture | None | Synthetic only | Allowed as deferred concept only |
| SyntheticAuthorizationConcept | Deferred authorization discussion only | Authorization architecture concept | Runtime RBAC or access grant | None | Synthetic only | Allowed as deferred concept only |

## Prohibited real-data flow paths

| Source | Prohibited target | Why prohibited | Current decision | Required future authorization before reconsideration |
| --- | --- | --- | --- | --- |
| Real patient record | Any Program 1 module | Would create real-data processing | Prohibited | Real-data governance, privacy/legal, security, and explicit future authorization |
| PHI/PII | Synthetic documentation layer | Would break synthetic-only boundary | Prohibited | PHI/PII processing approval and privacy/legal review |
| Production database | Architecture review layer | Would connect review to production data | Prohibited | Production governance and security review |
| Clinic appointment system | Program 1 flow | Would create scheduling integration risk | Prohibited | Appointment governance and explicit implementation authorization |
| Patient portal | Program 1 flow | Would create patient communication path | Prohibited | Patient communication governance and explicit authorization |
| EHR/EMR | Program 1 flow | Would create clinical data integration | Prohibited | Real-data, security, clinical safety, and production governance review |
| Staff workflow system | Program 1 flow | Would create workflow enforcement or staff-mediated patient communication risk | Prohibited | Workflow governance and explicit implementation authorization |
| Real audit logs | Program 1 audit concept | Would create real audit data handling | Prohibited | Audit/security architecture and privacy review |
| Real authorization events | Program 1 authorization concept | Would create runtime access-control data handling | Prohibited | Security architecture and implementation authorization |
| Real messages | Patient messaging concept | Would create patient communication handling | Prohibited | Patient communication governance and privacy/legal review |
| Real clinical notes | Clinical review concept | Would create clinical data processing | Prohibited | Clinical safety, real-data, privacy/legal, and implementation authorization |

## Read-only conceptual flow boundary

Read-only flow is a future concept only. Phase C does not authorize read-only runtime access, real system connections, database queries, EHR/EMR access, patient record viewing, or production data inspection.

## Write-back and mutation prohibition trace

| Prohibited path | Risk | Current decision | Future review dependency |
| --- | --- | --- | --- |
| Synthetic recommendation -> real patient instruction | Patient communication and treatment execution risk | Prohibited | Clinical safety, patient communication, and implementation authorization |
| Synthetic finding -> clinical note | Clinical write-path risk | Prohibited | Clinical accountability and implementation authorization |
| Synthetic review -> diagnosis entry | Autonomous or unsupported diagnosis risk | Prohibited | Clinical safety and accountability review |
| Synthetic review -> treatment execution | Treatment automation risk | Prohibited | Clinical safety and accountability review |
| Synthetic appointment placeholder -> appointment mutation | Scheduling mutation risk | Prohibited | Appointment governance review |
| Synthetic message placeholder -> patient message | Patient communication risk | Prohibited | Patient communication governance review |
| Synthetic task placeholder -> task assignment | Task engine/workflow risk | Prohibited | Workflow governance review |
| Synthetic outcome placeholder -> Outcome Evidence creation | Outcome Evidence activation risk | Prohibited | Outcome governance review |
| Synthetic authorization concept -> runtime access grant | Runtime authz risk | Prohibited | Security architecture review |
| Synthetic audit concept -> runtime audit event capture | Runtime audit behavior risk | Prohibited | Audit/security architecture review |
| Blocker status -> approval/override capability | Clearance or override semantics risk | Prohibited | Governance authorization; no automatic approval |

## Security, audit, and authorization conceptual flow limits

Security, audit, and authorization are conceptual and deferred. Phase C does not implement RBAC, runtime authorization, runtime authentication, audit capture, audit event storage, access logs, policy enforcement, approval gates, override gates, clearance workflow, or data access decisions.

## Boundary trace matrix

| Concept | Allowed in Phase C | Prohibited in Phase C | Data class allowed | Runtime status | Future dependency | Current decision |
| --- | --- | --- | --- | --- | --- | --- |
| Synthetic documentation | Markdown and text-only traces | Runtime code or real-data examples | Synthetic only | None | Explicit future authorization for any expansion | Allowed as docs only |
| Conceptual architecture discussion | Boundary discussion | Implementation authorization | Synthetic only | None | Hold-exit authorization | Allowed as docs only |
| Synthetic entity trace | Abstract trace paths | Real data mapping | Synthetic only | None | Future review required | Allowed as docs only |
| Read-only concept | Future concept discussion | Runtime read access | Synthetic only | Not implemented | Read-only authorization and validation | Deferred |
| Clinical review concept | Human review concept | Clinical deployment or validation | Synthetic only | Not implemented | Clinical safety review | Deferred |
| Patient communication concept | Prohibition discussion | Patient messaging or reminders | Synthetic only | Prohibited | Patient communication governance | Prohibited |
| Appointment mutation concept | Prohibition discussion | Scheduling changes | Synthetic only | Prohibited | Appointment governance | Prohibited |
| Write-capable concept | Prohibition trace | Mutation or writeback | Synthetic only | Prohibited | Separate future authorization | Prohibited |
| Audit concept | Deferred concept discussion | Runtime audit capture or storage | Synthetic only | Not implemented | Audit/security architecture review | Deferred |
| Authorization concept | Deferred concept discussion | Runtime RBAC or access grants | Synthetic only | Not implemented | Security architecture review | Deferred |
| Approval/override concept | Prohibition discussion | Approval, clearance, or override capability | Synthetic only | Prohibited | Separate governance authorization | Prohibited |
| Production deployment concept | Boundary discussion | Go-live or deployment automation | None | Prohibited | Production governance review | Prohibited |

## Explicit non-approval statement

Phase C does not approve implementation, production use, real-data use, PHI/PII processing, clinical deployment, go-live, runtime data flow, read-only runtime access, write-back behavior, runtime authorization, runtime audit logging, patient messaging, appointment mutation, workflow enforcement, clinical write workflows, or approval/clearance/override capability.

## Next-step decision

Recommended next phase: `Program 1 Architecture Review Track Phase D - Conceptual Read-Only Reference Boundary and Non-Mutation Model`.

If opened, Phase D should remain documentation-only and synthetic-only. Phase D must not introduce runtime implementation or real read-only access.

## Closure statement

Architecture Review Track Phase C closes with Program 1 still in pre-implementation hold. No runtime data flow, real-data ingestion, PHI/PII processing, production use, clinical deployment, read-only runtime access, write-back behavior, patient messaging, appointment mutation, workflow enforcement, audit capture, RBAC enforcement, approval/clearance/override capability, or go-live authorization is created.
